Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate synthase for opportunistic infections

Nilesh Zaware, Hitesh Sharma, Jie Yang, Ravi Kumar Vyas Devambatla, Sherry Queener, Karen S. Anderson, Aleem Gangjee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Infection by the parasite Toxoplasma gondii (tg) can lead to toxoplasmosis in immunocompromised patients such as organ transplant, cancer, and HIV/AIDS patients. The bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme is crucial for nucleotide synthesis in T. gondii and represents a potential target to combat T. gondii infection. While species selectivity with drugs has been attained for DHFR, TS is much more conserved across species, and specificity is significantly more challenging. We discovered novel substituted-9H-pyrimido[4,5-b]indoles 1-3 with single-digit nanomolar K i for tgTS, two of which, 2 and 3, are 28- and 122-fold selective over human TS (hTS). The synthesis of these compounds, and their structures in complex with tgTS-DHFR are presented along with binding measurements and cell culture data. These results show, for the very first time, that, in spite of the high degree of conservation of active site residues between hTS and the parasite TS, specificity has been accomplished via novel structures and provides a new target (TS) for selective drug development against parasitic infections.

Original languageEnglish
Pages (from-to)1148-1151
Number of pages4
JournalACS Medicinal Chemistry Letters
Volume4
Issue number12
DOIs
StatePublished - Dec 12 2013

Fingerprint

Thymidylate Synthase
Toxoplasmosis
Opportunistic Infections
Toxoplasma
Indoles
Transplants
Cell culture
Pharmaceutical Preparations
Species Specificity
Conservation
Parasitic Diseases
Nucleotides
Immunocompromised Host
Catalytic Domain
Parasites
Acquired Immunodeficiency Syndrome
Enzymes
Cell Culture Techniques
HIV
thymidylate synthase-dihydrofolate reductase

Keywords

  • active-site inhibitors
  • crystal structure
  • Opportunistic infection
  • thymidylate-synthase inhibitors
  • Toxoplasma gondii

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate synthase for opportunistic infections. / Zaware, Nilesh; Sharma, Hitesh; Yang, Jie; Devambatla, Ravi Kumar Vyas; Queener, Sherry; Anderson, Karen S.; Gangjee, Aleem.

In: ACS Medicinal Chemistry Letters, Vol. 4, No. 12, 12.12.2013, p. 1148-1151.

Research output: Contribution to journalArticle

Zaware, Nilesh ; Sharma, Hitesh ; Yang, Jie ; Devambatla, Ravi Kumar Vyas ; Queener, Sherry ; Anderson, Karen S. ; Gangjee, Aleem. / Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate synthase for opportunistic infections. In: ACS Medicinal Chemistry Letters. 2013 ; Vol. 4, No. 12. pp. 1148-1151.
@article{c7614b25218f42309e1563181af5a108,
title = "Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate synthase for opportunistic infections",
abstract = "Infection by the parasite Toxoplasma gondii (tg) can lead to toxoplasmosis in immunocompromised patients such as organ transplant, cancer, and HIV/AIDS patients. The bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme is crucial for nucleotide synthesis in T. gondii and represents a potential target to combat T. gondii infection. While species selectivity with drugs has been attained for DHFR, TS is much more conserved across species, and specificity is significantly more challenging. We discovered novel substituted-9H-pyrimido[4,5-b]indoles 1-3 with single-digit nanomolar K i for tgTS, two of which, 2 and 3, are 28- and 122-fold selective over human TS (hTS). The synthesis of these compounds, and their structures in complex with tgTS-DHFR are presented along with binding measurements and cell culture data. These results show, for the very first time, that, in spite of the high degree of conservation of active site residues between hTS and the parasite TS, specificity has been accomplished via novel structures and provides a new target (TS) for selective drug development against parasitic infections.",
keywords = "active-site inhibitors, crystal structure, Opportunistic infection, thymidylate-synthase inhibitors, Toxoplasma gondii",
author = "Nilesh Zaware and Hitesh Sharma and Jie Yang and Devambatla, {Ravi Kumar Vyas} and Sherry Queener and Anderson, {Karen S.} and Aleem Gangjee",
year = "2013",
month = "12",
day = "12",
doi = "10.1021/ml400208v",
language = "English",
volume = "4",
pages = "1148--1151",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate synthase for opportunistic infections

AU - Zaware, Nilesh

AU - Sharma, Hitesh

AU - Yang, Jie

AU - Devambatla, Ravi Kumar Vyas

AU - Queener, Sherry

AU - Anderson, Karen S.

AU - Gangjee, Aleem

PY - 2013/12/12

Y1 - 2013/12/12

N2 - Infection by the parasite Toxoplasma gondii (tg) can lead to toxoplasmosis in immunocompromised patients such as organ transplant, cancer, and HIV/AIDS patients. The bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme is crucial for nucleotide synthesis in T. gondii and represents a potential target to combat T. gondii infection. While species selectivity with drugs has been attained for DHFR, TS is much more conserved across species, and specificity is significantly more challenging. We discovered novel substituted-9H-pyrimido[4,5-b]indoles 1-3 with single-digit nanomolar K i for tgTS, two of which, 2 and 3, are 28- and 122-fold selective over human TS (hTS). The synthesis of these compounds, and their structures in complex with tgTS-DHFR are presented along with binding measurements and cell culture data. These results show, for the very first time, that, in spite of the high degree of conservation of active site residues between hTS and the parasite TS, specificity has been accomplished via novel structures and provides a new target (TS) for selective drug development against parasitic infections.

AB - Infection by the parasite Toxoplasma gondii (tg) can lead to toxoplasmosis in immunocompromised patients such as organ transplant, cancer, and HIV/AIDS patients. The bifunctional thymidylate synthase-dihydrofolate reductase (TS-DHFR) enzyme is crucial for nucleotide synthesis in T. gondii and represents a potential target to combat T. gondii infection. While species selectivity with drugs has been attained for DHFR, TS is much more conserved across species, and specificity is significantly more challenging. We discovered novel substituted-9H-pyrimido[4,5-b]indoles 1-3 with single-digit nanomolar K i for tgTS, two of which, 2 and 3, are 28- and 122-fold selective over human TS (hTS). The synthesis of these compounds, and their structures in complex with tgTS-DHFR are presented along with binding measurements and cell culture data. These results show, for the very first time, that, in spite of the high degree of conservation of active site residues between hTS and the parasite TS, specificity has been accomplished via novel structures and provides a new target (TS) for selective drug development against parasitic infections.

KW - active-site inhibitors

KW - crystal structure

KW - Opportunistic infection

KW - thymidylate-synthase inhibitors

KW - Toxoplasma gondii

UR - http://www.scopus.com/inward/record.url?scp=84890486360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890486360&partnerID=8YFLogxK

U2 - 10.1021/ml400208v

DO - 10.1021/ml400208v

M3 - Article

VL - 4

SP - 1148

EP - 1151

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 12

ER -